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Abstract
Therapeutic options are limited for patients infected with Acinetobacter baumannii due to its multidrug-resistance profile. So, the
search for new antimicrobials against this gram-negative bacterial pathogen has become a worldwide priority. The present study
aimed to evaluate the effects of 1,10-phenanthroline (phen), 1,10-phenanthroline-5,6-dione (phendione), [Ag(phendione)2]ClO4
(Ag-phendione) and [Cu(phendione)3](ClO4)2·4H2O (Cu-phendione) on 26 carbapenemase-producing A. baumannii strains. The
susceptibility to carbapenems was performed by detecting the metallo-beta-lactamase (MBL) genes by PCR and by determining
the MIC. Also, disk diffusion method was applied to evaluate the susceptibility to other antimicrobial classes. The test com-
pounds were evaluated on both planktonic- and biofilm-growing bacterial cells. The results revealed that all A. baumannii strains
had the intrinsic blaOXA-51 gene, and at least one of the blaOXA-23 or blaOXA-24 genes. The geometric mean MIC and minimum
bactericidal concentration (MBC) values, respectively, were as follows: Cu-phendione (1.56 and 2.30 μM), Ag-phendione (2.48
and 3.63 μM), phendione (9.44 and 9.70 μM), and phen (70.46 and 184.28 μM). The test compounds (at 0.5 ×MIC) affected the
biofilm formation and disrupted the mature biofilm, in a typically dose-dependent manner, reducing biomass and viability
parameters. Collectively, silver and copper-phendione derivatives presented potent antimicrobial action against planktonic-
and biofilm-forming cells of carbapenemase-producing A. baumannii.
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Introduction
Acinetobacter baumannii is a gram-negative opportunistic
bacterial pathogen able to cause human diseases, particularly
associated with nosocomial infections, which presents high
mortality rates [1]. Cross-transmission is the more important
route in the maintenance of the infectious agent in the hospital
environment and, consequently, in the occurrence of
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outbreaks related to A. baumannii [2]. The World Health
Organization (WHO) has released a global priority list con-
taining the main antimicrobial-resistant bacteria, aiming to
highlight and to stimulate the researches around the world to
focus on the development of new antimicrobial compounds
and novel effective treatment strategies against such human
pathogens. In this context, A. baumannii is at the top of the
WHO priority list, being considered the most alarming among
the multidrug-resistant (MDR) bacterial species.A. baumannii
is endemic in several healthcare-associated settings, present-
ing a prevalence rate of more than 10% among gram-negative
isolates, being particularly associated with pneumonia, septi-
cemia, meningitis, and urinary tract infection [3].
The abilities of A. baumannii to survive on dry and inani-
mate surfaces, to form biofilm and to acquire antimicrobial
resistance characteristics, without no doubt, contribute to its
wide spread in the hospital environments and increase the like-
lihood of causing nosocomial infections [1]. This species pro-
duces an intrinsic β-lactamase, oxacillinase, represented by
OXA-51. The genes encoding the blaOXA-51-like type β-
lactamases are chromosomally located in all isolates of
A. baumannii studied to date. The presence of carbapenemases
is the most common cause of resistance to carbapenems, and
the onset of metallo-β-lactamases (MBL) is becoming a thera-
peutic challenge [4]. The current therapeutic arsenal is usually
ineffective for the control of infections caused by A. baumannii
[1, 3].
Over the last years, metal-based drugs have been proven to
be of great relevance due to their therapeutic principles and
their pharmacological applications [5]. For instance, McCann
et al. [6] synthesized three new derivatives from 1,10-
phenanthroline (phen), which has been widely used as chelat-
ing agent and as molecular basis to synthesize new molecules
with different bioactive properties: 1,10-phenanthroline-5,6-
dione (phendione), [Ag(phendione)2]ClO4 (Ag-phendione)
and [Cu(phendione)3](ClO4)2·4H2O (Cu-phendione) [7].
In vitro and in vivo experimental studies have revealed that
phendione and its Ag+ and Cu2+ complexes have been pre-
sented the ability to alter the functioning and survival of a
variety of microorganisms such as bacteria, fungi and proto-
zoa [7, 8]. Corroborating these previous statements, Viganor
et al. [8] showed that Ag-phendione and Cu-phendione pre-
sented potent antimicrobial effects against both planktonic-
and biofilm-growing Pseudomonas aeruginosa cells, includ-
ing carbapenem-resistant clinical strains recovered from dif-
ferent human anatomical sites. In a preceding study, Santos
et al. [7] showed that both Ag-phendione and Cu-phendione
were well-tolerated in in vivo tests using Galleria mellonella
larvae and Swiss mice, which reinforces that these compounds
may represent a new class of antimicrobial agents with poten-
tial therapeutic applications. Considering all these beneficial
properties as well as the necessity to find new potential com-
pounds against A. baumannii, herein, the effects of phen,
phendione and its silver- and copper-derivatives were evalu-
ated on planktonic proliferation and on biofilm-forming
A. baumannii MDR strains.
Materials and methods
Chemicals
The clinically available antimicrobial agents, gentamicin
(GEN), ciprofloxacin (CIP), levofloxacin (LEV), tobramycin
(TOB), amikacin (AMI), and trimethoprim/sulfamethoxazole
(SUT), were purchased from Sensidisc (Diagnósticos
Microbiológicos Especializados - DME, São Paulo, Brazil).
Meropenem (MPM), imipenem (IPM), phen, crystal violet,
menadione, 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-
5-[phenylamine] carbonyl]-2H-tetrazolium hydroxide
(XTT), dimethyl sulfoxide (DMSO), AgNO3, and CuSO4·
5H2O were purchased from Sigma-Aldrich Chemical Co. (St
Louis, MO, USA). Luria-Bertani (LB) and blood agar (BA)
were purchased from Merck (Darmstadt, Germany). Mueller-
Hinton Agar (MHA) and Mueller-Hinton II broth (MHB-ca)
was purchased from Becton, Dickinson and Company (BD,
Sparks, MD, USA). Phendione, Ag-phendione, and Cu-
phendione were prepared in accordance with the methods de-
scribed in the literature [9]. All other reagents were of analyt-
ical grade.
Bacterial strains
Twenty-six non-duplicated A. baumannii strains collected
from patients hospitalized in 10 Brazilian hospitals in 2014
were included in this study. Strains were obtained from
distinct infection sites: tracheal aspirate (n = 6), tracheal
secretion (n = 5), sacral wound swab (n = 3), urine (n = 2),
fragment of bone tissue (n = 2), catheter tip (n = 2), frag-
ment of the gluteal region (n = 1), bronchoalveolar lavage
(n = 1), swab for cystostomy (n = 1), left lower limb wound
swab (n = 1), nasal swab (n = 1), and abdominal tissue (n =
1). Each A. baumannii strain used in the present study
came from only one patient, and it was representative of
different clones as assessed by PFGE genotyping [10];
consequently, each bacterial strain was isolated from only
one anatomical site regarding each individual. The strains
were identified by VITEK® 2 automated system. The ref-
erence strain of Pseudomonas aeruginosa ATCC 27853
and a clinical strain of P. aeruginosa (09HC), whose sus-
ceptibility profiles to MPM, IPM, phen, phendione, Ag-
phendione, and Cu-phendione were previously defined by
Viganor et al. [8] were used herein as quality control of the
antimicrobial tests.
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Determination of MIC and MBC of the carbapenems
The MIC and MBC for both MPM and IPM were evaluated
by microdilution method according to the Clinical and
Laboratory Standards Institute (CLSI) standard protocol
[11], using a 96-well microtiter plate with MHB-ca.
PCR for detection of prevalent OXA carbapenemases
The multiplex polymerase chain reaction (PCR) assay was
performed to verify the presence of blaOXA-23-like (501 bp),
blaOXA-24-like (246 bp), and blaOXA-58-like (599 bp) β-lactamase
encoding genes plus intrinsic blaOXA-51-like (353 bp), as previ-
ously described [12]. The amplification conditions were brief-
ly described as follows: initial denaturation at 94 °C for 5 min,
30 cycles at 94 °C for 25 s, followed by a cycle at 52 °C for
40 s and a cycle at 72 °C for 50 s, and a final elongation at
72 °C for 6 min. The PCR products were analyzed by electro-
phoresis with 1.4% agarose gels with 0.5× Tris–borate–EDTA
(TBE; 89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.0)
running buffer at 100 V for 1–2 h, then stained with 0.5 mg/
mL of ethidium bromide and detected under UV transillumi-
nation (Bio Rad Gel Doc 2000 with UV Trans Iluminator).
Antimicrobial susceptibility
Antimicrobial susceptibility test was performed and
interpreted according to the protocol recommended by CLSI
[11] by means of disk diffusion method to six antimicrobials:
GEN (10 μg), CIP (5 μg), LEV (5 μg), TOB (10 μg), AMI
(30 μg), and SUT (1.25/23.75 μg). Bacterial strains that
displayed resistance to three or more antimicrobial classes
were classified as MDR [13].
MICs and MBCs of phen, phendione, and its metal-
based compounds against planktonic bacterial
growth
The MIC and MBC values of the test compounds (phen,
phendione, Ag-phendione, and Cu-phendione) as well as sim-
ple salts (AgNO3 and CuSO4·5H2O) were determined by
microdilution method according to Viganor et al. [8] using a
96-well microtiter plate with MHB-ca containing 1.56–
200 μg/mL of each compound (starting from a 20 mM solu-
tion in DMSO). In all cases, the lowest concentration of each
compound that inhibited the bacterial growth, as ascertained
by the absence of visible turbidity in each well, was consid-
ered the MIC. The geometric mean MIC (GM-MIC) was cal-
culated, since this measure more realistically reflects the re-
sults of sets of numbers whose values change exponentially,
considering the amount of strains in each concentration [14].
Wells containingMHB-ca plus bacterial suspension, MHB-ca
plus test compound solutions, MHB-ca plus DMSO, MHB-ca
plus DMSO plus bacterial suspension, andMHB-ca only were
used as controls. An aliquot of 10 μL of wells showing no
growth were subcultured into nutrient agar plates for theMBC
determination of each test compound.
Effects of test compounds on biofilm formation
For this assay, the bacterial strains were seeded on nutrient
agar and incubated for 24 h at 35 ± 2 °C. Subsequently, the
cells were spiked in LB broth and incubated for 24 h at 35 ±
2 °C. Suspensions of bacterial strains were prepared in turbid
LB broth corresponding to the 0.5 McFarland standard (1.5 ×
108 CFU/mL). Then, 100 μL of each suspension was distrib-
uted in a 96-well polystyrene plate, which was incubated for
24 h at 35 ± 2 °C in the absence or in the presence of phen and
its derivatives at a concentration of 0.5 ×MIC. Thereafter, the
supernatants were collected and the wells were washed three
times with 200 μL of saline. To evaluate the biofilm biomass,
100 μL of violet crystal solution (0.3% w/v) was added to the
wells, and after 15 min, the wells were washed with running
water to remove the excess of the dye. Finally, after drying the
plates, the violet crystal adsorbed on the biofilm was diluted
by the addition of 100 μL of 70% ethanol with 10% isopropyl
alcohol. The absorbance was measured spectrophotometrical-
ly using a Thermomax Molecular Device microplate reader at
540 nm [8, 15]. The metabolic activity after treatment with
phen, phendione, and its derivatives was evaluated by the
reduction of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-
5-[phenylamine) carbonyl]-2H-tetrazolium (XTT) as previ-
ously described by Viganor et al. [8]. After the biofilm forma-
tion period, in the presence and absence of equivalent concen-
trations, the supernatants were removed and the biofilm was
washed 3 times with PBS for removal of the non-adherent
cells. Then, 158 μL of PBS, 40 μL of XTT (1 mg/mL) and
2 μL of menadione (4 mM) were added. The plate was incu-
bated for 3 h at 35 ± 2 °C under the light. At the end of the
incubation, XTT reduction was measured at 490 nm for the
evaluation of metabolically active cells [8, 15].
Effects of test compounds on the mature biofilm
Bacterial strains were seeded in BA and incubated for 24 h at
35 ± 2 °C. Then, bacterial suspensions were made at 0.5
McFarland standard turbidity in LB broth. Subsequently,
100 μL of the suspension was distributed into 96-well poly-
styrene plates. After the biofilm formation (24 h), the com-
pounds were added to the wells at different concentrations
(1.56–25 μg/mL). The systems were incubated for another
24 h at 35 ± 2 °C. At the end of the incubation period, staining
was performed with crystal violet and XTT and biofilm via-
bility was measured as previously described [8, 15].
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Statistics
The experiments were carried out in biological triplicates.
Data were expressed as mean ± standard deviation. The results
were evaluated through analysis of variance (ANOVA), with
a statistical significance level of 95% (p < 0.05). The software
used for analysis was GraphPad Prism 7.
Results
Confirmation of carbapenems’ susceptibility
Our results confirmed that all the A. baumannii strains were
resistant to both carbapenems. The strains showedMIC values
for MPM ranging from 16 to 64 μg/mL and for IPM varying
from 32 to 128 μg/mL (Table 1). All the A. baumannii strains
harbored at least one of the evaluated carbapenemase gene.
The intrinsic blaOXA-51-like gene was detected in all 26 clinical
strains studied, while 24 (92.3%) were positive for the blaOXA-
23-like gene and 2 (7.7%) were positive for the blaOXA-24-like
gene. Conversely, none of the strains had the blaOXA-58-like
gene.
Antimicrobial susceptibility profiles
The disk diffusion method was performed to ascertain the
susceptibility profiles to other six antimicrobials belonging
to different classes. All strains were resistant to CIP and
LEV, both antimicrobials belong to the quinolone class. The
resistance percentages for the remaining tested antimicrobials
were as follows: 80.9% for SUT, 76.9% for GEN, 73.1% for
TOB, and 50% for AMI. Our results pointed out that all stud-
ied Brazilian clinical strains of A. baumannii showed high
percentages of antimicrobial resistance. Corroborating this
finding, 80.7% (21/26) A. baumannii strains were resistant
to at least two other classes of antimicrobials beyond β-
lactams, being classified as MDR strains.
MICs and MBCs of phen, phendione, and its metal-
based compounds against planktonic bacterial
growth
The results of antimicrobial susceptibility test for phen,
phendione, Ag-phendione, and Cu-phendione are summa-
rized in Table 1. Both Cu-phendione (GM-MIC = 1.63 μM)
and Ag-phendione (GM-MIC = 2.48 μM) were extremely ef-
fective in inhibiting planktonic bacterial growth followed by
phendione (GM-MIC = 9.44 μM) and phen (GM-MIC =
70.46 μM). The silver salt (AgNO3) showed moderate growth
inhibition activity (GM-MIC = 39.6 μM), while the copper
salt (CuSO4·5H2O) was considered inactive. Aqueous
DMSO, which was used as solvent for all test compounds,
did not interfere with the bacterial growth (data not shown).
The MBC values were also determined, showing the
following potency pattern: Cu-phendione (GM-MBC =
2.30 μM) > Ag-phendione (GM-MBC = 3.63 μM) >
phendione (GM-MBC = 9.70 μM) > phen (GM-MBC =
184.28 μM).
Effects of phen, phendione, and its metal-based
compounds on the biofilm
The effect of tested compounds on biofilm formation by 26
A. baumannii strains were analyzed in terms of total biomass
and cellular metabolic activity. For these experiments, bacte-
rial cells were incubated with the compounds at 0.5 ×MIC
value during the whole period of biofilm formation (24 h)
on a polystyrene surface. Phen, phendione, Ag-phendione
and Cu-phendione were able to inhibit the biofilm formation,
Table 1 Effects of test compounds on planktonic growth of A. baumannii clinical strains
Compounds Range (μg/mL) MIC50 (μg/mL) MIC90 (μg/mL) GM-MIC, μg/mL (μM) GM-MBC, μg/mL (μM)
MPM 16–64 32 64 44.42 (ND) ND
IPM 32–128 64 128 61.54 (ND) ND
Phen 12.5–25 12.5 12.5 12.98 (70.46 μM) 36.53 (184.28 μM)
Phendione 1.562–6.25 1.562 1.562 1.98 (9.44 μM) 2.04 (9.70 μM)
Ag-phendione 1.562 1.562 1.562 1.562 (2.48 μM) 2.28 (3.63 μM)
Cu-phendione 1.562 1.562 1.562 1.562 (1.63 μM) 2.22 (2.30 μM)
AgNO3 6.25–12.5 6.25 6.25 6.73 (39.6 μM) ND
CuSO4·5H2O > 200 > 200 > 200 ND ND
MIC50 and MIC90, correspond to the minimum concentration of test compound required to inhibit 50% and 90% of the clinical bacterial strains,
respectively
MPM meropenem, IPM imipenem, phen 1,10-phenanthroline, phendione 1,10-phenanthroline-5,6-dione, Ag-phendione [Ag(phendione)2]ClO4, Cu-
phendione [Cu(phendione)3](ClO4)2·4H2O, GM-MIC geometric mean of MIC, GM-MBC geometric mean of MBC, ND not determined
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reducing the biomass by approximately 79%, 76%, 61%, and
57%, respectively (Fig. 1a and b), and the metabolic activity
by around 73%, 66%, 43%, and 56%, respectively (Fig. 1c
and d).
The ability of tested compounds to kill the A. baumannii cells
embedded inside the mature biofilm structure was also assessed.
To this goal, different concentrations of phen, phendione, Ag-
phendione, and Cu-phendione were added to the 24-h mature
biofilm of A. baumannii followed by an additional incubation
of 24 h. Phendione and its metal-based derivatives were able to
reduce the biofilm viability in a typically dose-dependent manner
(Fig. 2). In this set of experiments, Cu-phendione was the most
potent compound, presenting the lowest concentration required
to reduced 50% of biofilm viability (IC50 = 13.54 μM), followed
by Ag-phendione (IC50 = 22.05 μM) and phendione (IC50 =
34.58 μM) (Fig. 2).
Discussion
Acinetobacter baumannii is a human opportunistic pathogen,
whose infections are notoriously difficult to treat due to the
intrinsic and acquired antimicrobial resistance often limiting
the effective therapeutic options. The bacterial persistence in
the hospital environments exposes it to the constant selective
pressure imposed by the antimicrobials, which, in addition to
its remarkable ability to acquire resistance, led to the emer-
gence of MDR strains [16]. To worsen this scenario,
carbapenem-resistant A. baumannii strains have a high poten-
tial for nosocomial dissemination [2]. In these context, we
decided to select strains of A. baumannii resistant to carbapen-
ems, since this antibacterial class is often used as “last-line
agents” or “antibiotics of last resort”when patients with infec-
tions become gravely ill or are suspected of harboring resistant
bacteria [17].
All the strains selected for this study proved to be pheno-
typically resistant to carbapenem, and they harbored at least
one carbapenemase gene. The carbapenem resistance strate-
gies in A. baumannii include the production of MBLs, mainly
β-lactamase class D (type OXA), which is responsible for this
phenotype [18]. In our study, the blaOXA-51 gene was detected
in all strains along with blaOXA-23 or blaOXA-24 genes. The sub-
groups of carbapenem-hydrolyzing OXAs, such as the OXA-
23, OXA-24, OXA-51, and OXA-58 subgroups, are
Fig. 1 Effects of phen, phendione, Ag-phendione, and Cu-phendione on
biofilm formation by 26 A. baumannii clinical strains. Biofilm biomass
was measured by crystal violet incorporation and absorbance value at
540 nm (a and b), and cellular viability was quantified by XTT and
absorbance value at 490 nm (c and d). The distribution of biofilm biomass
(a) and viability (c) in each clinical strain regarding each analyzed system
was plotted. In parallel, the values representing the mean ± standard
deviation concerning biofilm biomass (b) and viability (d) for each ana-
lyzed system are also shown. The gray lines in a and c indicate the
arithmetic mean of the production of biofilm in each system. Stars denote
a significant difference between untreated and treated bacterial cells
(P < 0.05; one-way ANOVA, Dunnett’s multiple comparison test)
1707Braz J Microbiol (2020) 51:1703–1710
considered prevalent in A. baumannii [1, 19]. These enzymes
are a major worldwide concern, because they present the pos-
sibility that all isolates of A. baumannii should be able to
become resistant to carbapenems [20].
In addiction of the carbapenems’ susceptibility profile, the
knowledge of the susceptibility of the strains to other antimi-
crobial classes, mainly in relation to the existence of other
resistance mechanisms, are important data for a better evalu-
ation of the antimicrobial activity of the compounds derived
from phen, highlighting the possibility of different resistance
mechanisms presented by these strains interfere with the ac-
tion of these compounds, e.g., the efflux systems or change of
target site related to resistance to fluoroquinolones and ami-
noglycoside, respectively [21]. In this context, we evidenced a
high rate of MDR among the strains of A. baumannii selected
for this study highlight of the existence of different mecha-
nism of resistance.
The searching for new compounds with anti-A. baumannii
action is urgently required. However, due to the lack perspec-
tive regarding the release of new antimicrobials in the global
market, this need is far from to be achieved. In order to con-
tribute in this avenue, we investigated the possible antimicro-
bial activity of phen and phendione-based compounds on
carbapenem-resistant A. baumannii strains. Our results
showed that phendione and its Ag+ and Cu2+ complexes
showed bactericidal action on planktonic-growing
A. baumannii cells in concentrations < 10 μM, with Cu-
phendione having the most powerful action. These com-
pounds were already tested on another gram-negative, ubiqui-
tous and multidrug-resistant bacterium, P. aeruginosa [8].
Interestingly, the MICs of phendione and its metal-
derivatives were at least 4 times lower for A. baumannii when
compared to P. aeruginosa [8].
In general, our results demonstrated that the low concen-
trations of Ag-phendione and Cu-phendione exhibit a potent
antimicrobial effect against A. baumannii planktonic cells.
The low MIC values found here contrast with the elevated
concentrations calculated to kill G. mellonella larvae and
Swiss mice in in vivo experiments, reinforcing that these com-
pounds were well tolerated by these model organisms [22].
These data are relevant, because in a process of developing
new drugs it is crucial to evaluate and select those that have a
balanced efficacy/safety profile. Thus, efficacy and safety data
generated in vitro and in vivo can be used to calculate a clin-
ical therapeutic index of a drug candidate at an early stage
[23]. Therefore, the results obtained in our study reinforce
the antimicrobial potential of phendione-based compounds,
particularly Cu-phendione, stimulating the determination of
important and crucial pharmacodynamic and phamacocynetic
properties of these promising compounds.
Acinetobacter baumannii has the ability to form biofilm on
inert surfaces, contributing to the ecological success of this
pathogen in the hospital environment [24]. Also, the
A. baumannii biofilm lifestyle permits the pathogen to survive
for long periods even in an abiotic surface, which increases its
probability of causing nosocomial infections and outbreaks
[24], representing an important virulence attribute [25].
Biofilm is a well-known structure of resistance against both
chemical and physical stressors, which is produced by various
microorganisms, including human pathogenic bacteria [1, 26].
The present study demonstrated that all test compounds sig-
nificantly reduced the biofilm formation, considering both
biomass and metabolic activity, in A. baumannii isolates on
polystyrene surface at concentrations up to 10 times the MIC
calculated to the planktonic growth. In addition, phendione,
Ag-phendione, and Cu-phendione were able to significantly
reduce the viability of bacterial cells evenwhen embedded in a
mature biofilm structure. Similar results were reported by
Viganor et al. [8] to biofilm formed by P. aeruginosa, in
which phendione and its Ag+ and Cu+2 complexes were able
Fig. 2 Effects of phen, phendione, Ag-phendione, and Cu-phendione on
mature biofilm formed by A. baumannii clinical strains. The values rep-
resent the mean ± standard deviation concerning biofilm viability for each
analyzed compound. Stars denote a significant difference between un-
treated and treated bacterial cells (P < 0.05; one-way ANOVA,
Dunnett’s multiple comparison test)
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to disrupt the mature biofilm in a typically dose-dependent
fashion. The model of disarticulation of mature biofilms by
chelating agents, such as phen and phendione, is consolidated
on bacterial biofilms. In this context, Tay et al. [27] showed
that phendione eradicated the biofilm formation in
Enterococcus faecalis suggesting a mechanism of chelating
action of essential metals (Zn2+, Fe2+, Ca2+, Cu2+, Co2+,
Mn2+, and Ni2+) for bacterian metabolism. In P. aeruginosa,
the negatively charged extracellular DNA (eDNA) interacts
with cations, such as Mg2+ and Ca2+, stabilizing the extracel-
lular matrix [28]. So, the chelating agents sequester the cations
from eDNA, leading to its destabilization [29], leading to its
disarticulation. It would be interesting to further explore the
interference mechanisms of these compounds in the biofilm
formation, which can open new windows to use these com-
pounds as an anti-virulence (anti-biofilm) strategy in order to
combat carbapenemase-producing A. baumannii.
In conclusion, our results pointed out that phendione-based
compounds, particularly Cu-phendione, presented potent an-
timicrobial action against both planktonic- and biofilm-
forming cells of A. baumannii MDR strains, including
carbapenemase-producing ones, indicating that these com-
pounds may represent a novel class of antimicrobial agents
with potential therapeutic applications.
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